People's Health Press
ISSN 2096-2738 CN 11-9370/R

Source Journal for Chinese Scientific and Technical Papers and Citations
Source Journal for Annual Report for Chinese Academic Journal Impact Factors(2022)
Indexed Journals in the Database of the Chemical Abstracts Service (CAS), USA
Indexed Journals in the Database of the Japan Science and Technology Agency (JST)

  • Official WeChat

  • Official Weibo

  • Electronic Journal of Emerging Infectious Diseases ›› 2026, Vol. 11 ›› Issue (2): 35-40.doi: 10.19871/j.cnki.xfcrbzz.2026.02.007

    • Original Articles • Previous Articles     Next Articles

    Study on the effect of ganciclovir injection combined with recombinant human interferon α-1b in the treatment of RSV pneumonia in children

    He Yaohong, Tan Yanguo, Chen Jin, Qu Shuang   

    1. Department of Respiratory Medicine, Fuxing Hospital, Capital Medical University, Beijing 100038, China
    • Received:2025-04-17 Online:2026-04-30 Published:2026-05-18

    Abstract: Objective To investigate the therapeutic efficacy of ganciclovir injection combined with recombinant human interferon alpha-1b on children with respiratory syncytial virus (RSV) pneumonia, providing a basis for clinical diagnosis and treatment of RSV pneumonia. Method 105 pediatric patients with RSV pneumonia (admitted from December 2021 to December 2023, aged 3-8 years) were randomly separated into combination group (35 cases) , control group (35 cases), and regular group (35 cases) in Fu Xing Hospital, Capital Medical University. The regular group received conventional treatment, the control group was treated with recombinant human interferon α-1b, and the combination group was treated with ganciclovir injection combined with recombinant human interferon α-1b(including antipyretic, expectorant, antitussive, oxygen therapy and basic antiviral therapy). Result The total effective rate of the combination group (94.29%, 33/35) was higher than that of the control group (68.57%, 24/35) and regular group (57.14%, 20/35) (all P<0.05). The improvement of clinical indicators such as cough[(3.96±0.88)d], wheezing[(3.39±0.85)d], and dyspnea[(1.62±0.30)d] in the combination group was better than that in the control group[(6.35±1.17)d, (5.57±1.12)d, (3.27±0.69)d, respectively] and regular group[(7.59±1.34)d, (6.89±1.27)d, (4.62±0.84)d, respectively] (all P<0.05). After treatment, the levels of tumor necrosis factor alpha (TNF-α), procalcitonin (PCT), interleukin (IL)-10, CD8+, and immunoglobulin E (IgE) in both groups of children decreased, while CD4+ increased. And the improvement amplitude of the combination group was higher than that of the control group and regular group (all P<0.05). Conclusion The combination of ganciclovir injection and recombinant human interferon α-1b can improve the clinical symptoms, reduce inflammatory response and improve immune function in children with RSV pneumonia, the efficacy is certain, with definite efficacy and good safety.

    Key words: Respiratory syncytial virus pneumonia, Recombinant human interferon α-1b, Ganciclovir injection, Efficacy

    CLC Number: